BVAX.F Stock Overview
A clinical-stage immunotherapeutic company, engages in developing antiviral and anticancer vaccine platforms.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
BioVaxys Technology Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.05 |
| 52 Week High | CA$0.076 |
| 52 Week Low | CA$0.0091 |
| Beta | 0.069 |
| 11 Month Change | -19.35% |
| 3 Month Change | -15.25% |
| 1 Year Change | 163.16% |
| 33 Year Change | -71.91% |
| 5 Year Change | n/a |
| Change since IPO | -83.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| BVAX.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.9% | 0.3% | 0.7% |
| 1Y | 163.2% | 17.4% | 23.3% |
Return vs Industry: BVAX.F exceeded the US Pharmaceuticals industry which returned 17.4% over the past year.
Return vs Market: BVAX.F exceeded the US Market which returned 23.3% over the past year.
Price Volatility
| BVAX.F volatility | |
|---|---|
| BVAX.F Average Weekly Movement | 14.9% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: BVAX.F's share price has been volatile over the past 3 months.
Volatility Over Time: BVAX.F's weekly volatility has decreased from 34% to 15% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Chris Passin | biovaxys.com |
BioVaxys Technology Corp., a clinical-stage immunotherapeutic company, engages in developing antiviral and anticancer vaccine platforms. It develops BVX-0320, a SARS-CoV-2 vaccine; BVX-1021, a vaccine for the strain of coronavirus that causes SARS1; and BVX-0918, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, a novel diagnostic platform to identify a T-cell immune response to the presence of SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions.
BioVaxys Technology Corp. Fundamentals Summary
| BVAX.F fundamental statistics | |
|---|---|
| Market cap | US$11.25m |
| Earnings (TTM) | -US$9.17m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs BVAX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BVAX.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$12.57m |
| Earnings | -CA$12.57m |
Last Reported Earnings
Jul 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.057 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BVAX.F perform over the long term?
See historical performance and comparison